Clinical Trials
15 trialsNCT06492122 2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1 Recruiting
NCT06052306 2026-05-18
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer
Phase 1 Active not recruiting
NCT07244341 2026-05-15
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting
NCT04853498 2026-03-31
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT06193486 2026-03-31
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT05613894 2025-10-31
CaboLu
University of Utah
Phase 1 Recruiting
NCT05544227 2025-07-23
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Williams Cancer Foundation
Phase 1 Completed
NCT04629781 2024-08-01
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Swiss Cancer Institute
Phase 1 Terminated
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT05252364 2024-03-21
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
Hinova Pharmaceuticals Inc.
Phase 1 Completed
NCT04879589 2023-04-28
Phase 1 Study of ATRS-2002 in Healthy Male Adults
Syneos Health
Phase 1 Withdrawn
NCT05533203 2023-01-23
Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shanghai Humantech Biotechnology Co. Ltd
Phase 1 Unknown
NCT03780075 2022-05-12
Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1 Unknown
NCT03403595 2018-01-18
177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1 Unknown